Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Urinary analyte screening: a noninvasive detection method for Down syndrome?

J A Canick1, L H Kellner, L A Cole

  • 1Dept of Pathology and Laboratory Medicine, Women and Infants Hospital, Brown University School of Medicine, Providence, RI, USA. jcanick@wihri.org

Molecular Medicine Today
|April 14, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extending the provision of cell-free DNA screening for trisomy 21.

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

First trimester pre-eclampsia screening: why delay implementation?

BJOG : an international journal of obstetrics and gynaecology·2017
Same author

What will be the role of first-trimester ultrasound if cell-free DNA screening for aneuploidy becomes routine?

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2014
Same author

hCG physiology.

Placenta·2013
Same author

Reply: To PMID 23673229.

American journal of obstetrics and gynecology·2013
Same author

First-trimester hyperglycosylated human chorionic gonadotropin and development of hypertension.

Prenatal diagnosis·2013

Maternal urine screening for Down syndrome shows potential for improved accuracy and cost-effectiveness. However, variable results mean its clinical value for detecting Down syndrome requires further investigation.

Area of Science:

  • Biochemistry
  • Genetics
  • Maternal-Fetal Medicine

Background:

  • Prenatal screening for Down syndrome currently uses maternal serum markers with 60-80% detection rates and a 5% false positive rate.
  • Human chorionic gonadotropin (hCG) is a key serum marker, but its major urinary metabolite, beta core fragment (beta CF), is being explored for improved screening.

Purpose of the Study:

  • To evaluate the potential of using beta core fragment (beta CF) and other maternal urine markers for Down syndrome screening.
  • To determine if maternal urine screening offers a more accurate, simpler, and cost-effective alternative to current serum marker tests.

Main Methods:

  • Analysis of beta core fragment (beta CF) and other markers in maternal urine samples.
  • Comparison of screening performance with established maternal serum marker tests.

Related Experiment Videos

Main Results:

  • Studies suggest beta CF in maternal urine may enhance Down syndrome detection rates.
  • Recent findings regarding maternal urine marker variability have been inconsistent.
  • The ease and safety of urine-based testing could increase its adoption.

Conclusions:

  • Maternal urine screening, particularly using beta CF, holds promise for improving Down syndrome detection.
  • The clinical utility of maternal urine screening for Down syndrome is not yet definitively established due to inconsistent results.